Skip Navigation



REIG JOFRE is a pharmaceutical company that was created with the strong conviction of making health universal, bringing from the most basic to the most innovative solutions to people all over the world. REIG JOFRE is the key step between research and cure. To provide pioneering, high-impact solutions, they have a cutting-edge technological production, they are in continuous collaboration with other innovative companies, researchers and startups and they constantly invest in I+D+i.

Since 1929 they investigate, develop, manufacture and market pharmaceutical products that are essential for people's health, under three main areas: Pharmaceutical Technologies, specialised in sterile and lyophilised injectables and antibiotics derived from penicillin; Specialty Pharmacare in Dermatology and Osteoarticular, mainly; and Consumer Healthcare, with products aimed at consumers under the Forté Pharma brand, mainly in France, Belgium, Spain and Portugal, and other OTC products.

REIG JOFRE is listed on the Spanish stock market under the ticker RJF and is the fifth largest Spanish pharmaceutical laboratory in terms of turnover listed on the stock market. Its track record supports its capacity to adapt and its experience in industrialisation to meet the global health needs of today and tomorrow.

REIG JOFRE has 4 development and production centres in Europe (2 in Toledo, 1 in Barcelona and 1 in Malmö), its own teams in Spain, France, Portugal, Belgium, Sweden, the United Kingdom and Poland, and more than 1,300 employees. It has an extensive network of business partners in more than 70 countries. The company closed 2023 with a turnover of 316 million euros in sales (+17% vs. 2022) and an EBITDA of 35 million euros (+15% vs. 2022).



217 KBMorningstar - Quantitative Report (15 June 2024 08:16)1,39 MBLighthouse - Coverage report - Initiation of Coverage